{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:28:47Z","timestamp":1792708127715,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 [National Cancer Institute Community Oncology Research Program (NCORP)] and Aurora NCORP Research Base grant (UG1CA189867)"],"award-info":[{"award-number":["U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), UG1CA189867 [National Cancer Institute Community Oncology Research Program (NCORP)] and Aurora NCORP Research Base grant (UG1CA189867)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11060-026-05788-w","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:15:43Z","timestamp":1789470943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The evolution of RTOG and NRG Oncology CNS tumors clinical trials"],"prefix":"10.1007","volume":"179","author":[{"given":"Kavita","family":"Sehrawat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yin C.","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Vogelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnab","family":"Chakravarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Lassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Raleigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"Sulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Machtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Thu","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinai","family":"Gondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4812-5713","authenticated-orcid":false,"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"5","key":"5788_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1097\/00000421-200110000-00018","volume":"24","author":"RB Jenkins","year":"2001","unstructured":"Jenkins RB et al (2001) Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am J Clin Oncol 24(5):506\u2013508","journal-title":"Am J Clin Oncol"},{"issue":"23","key":"5788_CR2","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.21.02543","volume":"40","author":"AB Lassman","year":"2022","unstructured":"Lassman AB et al (2022) Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. J Clin Oncol 40(23):2539\u20132545","journal-title":"J Clin Oncol"},{"issue":"32","key":"5788_CR3","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31(32):4085\u20134091","journal-title":"J Clin Oncol"},{"issue":"1","key":"5788_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11060-016-2288-5","volume":"131","author":"MR Gilbert","year":"2017","unstructured":"Gilbert MR et al (2017) NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. J Neurooncol 131(1):193\u2013199","journal-title":"J Neurooncol"},{"issue":"8","key":"5788_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708","journal-title":"N Engl J Med"},{"issue":"7","key":"5788_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1093\/neuonc\/noab011","volume":"23","author":"JS Wefel","year":"2021","unstructured":"Wefel JS et al (2021) Neurocognitive, symptom, and health-related quality of life outcomes of a randomized trial of bevacizumab for newly diagnosed glioblastoma (NRG\/RTOG 0825). Neuro Oncol 23(7):1125\u20131138","journal-title":"Neuro Oncol"},{"issue":"2","key":"5788_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/neuonc\/noaf221","volume":"28","author":"A Omuro","year":"2026","unstructured":"Omuro A et al (2026) Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma. Neuro Oncol 28(2):371\u2013382","journal-title":"Neuro Oncol"},{"issue":"1","key":"5788_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11060-017-2558-x","volume":"137","author":"AN Ali","year":"2018","unstructured":"Ali AN et al (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137(1):39\u201347","journal-title":"J Neurooncol"},{"key":"5788_CR9","unstructured":"Nelson DF et al (1988) Combined modality approach to treatment of malignant gliomas\u2013re-evaluation of RTOG 7401\/ECOG 1374 with long-term follow-up: a joint study of the radiation therapy oncology group and the Eastern cooperative oncology group. NCI Monogr 1988(6):279\u2013284"},{"issue":"23","key":"5788_CR10","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","volume":"303","author":"MD Walker","year":"1980","unstructured":"Walker MD et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303(23):1323\u20131329","journal-title":"N Engl J Med"},{"issue":"8","key":"5788_CR11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1535::AID-CNCR17>3.0.CO;2-0","volume":"77","author":"M Werner-Wasik","year":"1996","unstructured":"Werner-Wasik M et al (1996) Final report of a phase I\/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83\u2009\u2013\u200902. Cancer 77(8):1535\u20131543","journal-title":"Cancer"},{"issue":"2","key":"5788_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0360-3016(93)90340-2","volume":"25","author":"DF Nelson","year":"1993","unstructured":"Nelson DF et al (1993) Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma\u2013possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25(2):193\u2013207","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5788_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","volume":"47","author":"E Shaw","year":"2000","unstructured":"Shaw E et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90\u2009\u2013\u200905. Int J Radiat Oncol Biol Phys 47(2):291\u2013298","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5788_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","volume":"60","author":"L Souhami","year":"2004","unstructured":"Souhami L et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93\u2009\u2013\u200905 protocol. Int J Radiat Oncol Biol Phys 60(3):853\u2013860","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5788_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00165372","volume":"4","author":"PD Kurup","year":"1986","unstructured":"Kurup PD et al (1986) Fast neutron therapy for malignant astrocytomas. A review. J Neurooncol 4(2):123\u2013129","journal-title":"J Neurooncol"},{"issue":"1","key":"5788_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0360-3016(97)00485-9","volume":"40","author":"CB Scott","year":"1998","unstructured":"Scott CB et al (1998) Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90\u2009\u2013\u200906. Int J Radiat Oncol Biol Phys 40(1):51\u201355","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5788_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11060-006-9251-9","volume":"82","author":"CD Turner","year":"2007","unstructured":"Turner CD et al (2007) Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol 82(1):95\u2013101","journal-title":"J Neurooncol"},{"issue":"5","key":"5788_CR18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.ijrobp.2012.10.008","volume":"85","author":"A Chakravarti","year":"2013","unstructured":"Chakravarti A et al (2013) RTOG 0211: a phase 1\/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 85(5):1206\u20131211","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"5788_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO.2000.18.6.1254","volume":"18","author":"J Del Rowe","year":"2000","unstructured":"Del Rowe J et al (2000) Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18(6):1254\u20131259","journal-title":"J Clin Oncol"},{"issue":"4","key":"5788_CR20","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2018.11.008","volume":"103","author":"FS Lieberman","year":"2019","unstructured":"Lieberman FS et al (2019) Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420. Int J Radiat Oncol Biol Phys 103(4):878\u2013886","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5788_CR21","first-page":"252","volume":"19","author":"S Chang","year":"2017","unstructured":"Chang S et al (2017) Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol 19(2):252\u2013258","journal-title":"Neuro Oncol"},{"issue":"8","key":"5788_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","volume":"32","author":"JG Cairncross","year":"2014","unstructured":"Cairncross JG et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32(8):783\u2013790","journal-title":"J Clin Oncol"},{"issue":"10103","key":"5788_CR23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","volume":"390","author":"MJ van den Bent","year":"2017","unstructured":"van den Bent MJ et al (2017) Interim results from the CATNON trial (EORTC study 26053\u2009\u2013\u200922054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390(10103):1645\u20131653","journal-title":"Lancet"},{"issue":"10172","key":"5788_CR24","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U et al (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet 393(10172):678\u2013688","journal-title":"Lancet"},{"key":"5788_CR25","unstructured":"Oncology N (2021) NRG-BN011: A phase III trial of radiotherapy with lomustine and temozolomide versus radiotherapy with temozolomide alone in Patients with newly diagnosed MGMT-methylated glioblastoma. Available at: NRG Oncology Clinical Trials website. Accessed 8 Sep 2026"},{"issue":"14","key":"5788_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner JC et al (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374(14):1344\u20131355","journal-title":"N Engl J Med"},{"issue":"3","key":"5788_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.ijrobp.2014.11.012","volume":"91","author":"BJ Fisher","year":"2015","unstructured":"Fisher BJ et al (2015) Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys 91(3):497\u2013504","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5788_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-015-1845-7","volume":"124","author":"MA Vogelbaum","year":"2015","unstructured":"Vogelbaum MA et al (2015) Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. J Neurooncol 124(3):413\u2013420","journal-title":"J Neurooncol"},{"issue":"3","key":"5788_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/neuonc\/noaa168","volume":"23","author":"KA Jaeckle","year":"2021","unstructured":"Jaeckle KA et al (2021) CODEL: phase III study of RT, RT\u2009+\u2009TMZ, or TMZ for newly diagnosed 1p\/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol 23(3):457\u2013467","journal-title":"Neuro Oncol"},{"issue":"8","key":"5788_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722","journal-title":"N Engl J Med"},{"issue":"7","key":"5788_CR31","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/neuonc\/nov011","volume":"17","author":"AB Lassman","year":"2015","unstructured":"Lassman AB et al (2015) Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol 17(7):992\u2013998","journal-title":"Neuro Oncol"},{"issue":"2","key":"5788_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman AB et al (2023) Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro Oncol 25(2):339\u2013350","journal-title":"Neuro Oncol"},{"issue":"27","key":"5788_CR33","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO-25-00618","volume":"43","author":"AB Lassman","year":"2025","unstructured":"Lassman AB et al (2025) Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II\/III Clinical Trial. J Clin Oncol 43(27):3032\u20133040","journal-title":"J Clin Oncol"},{"issue":"12","key":"5788_CR34","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/S1470-2045(24)00633-8","volume":"25","author":"EA Mellon","year":"2024","unstructured":"Mellon EA (2024) The power of three: hypofractionation, protons, and molecular imaging in glioblastoma radiotherapy. Lancet Oncol 25(12):1514\u20131516","journal-title":"Lancet Oncol"},{"key":"5788_CR35","unstructured":"ClinicalTrials.gov (2026) A randomized phase III study comparing temporally-Modulated Pulsed Radiation Therapy (TMPRT) versus standard radiation therapy with temozolomide for adults with newly diagnosed MGMT-unmethylated glioblastoma"},{"issue":"3","key":"5788_CR36","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross G et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337\u2013343","journal-title":"J Clin Oncol"},{"issue":"1","key":"5788_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/neuonc\/nos273","volume":"15","author":"M Weller","year":"2013","unstructured":"Weller M et al (2013) Standards of care for treatment of recurrent glioblastoma\u2013are we there yet? Neuro Oncol 15(1):4\u201327","journal-title":"Neuro Oncol"},{"issue":"6","key":"5788_CR38","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.22.00164","volume":"41","author":"CI Tsien","year":"2023","unstructured":"Tsien CI et al (2023) NRG Oncology\/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. J Clin Oncol 41(6):1285\u20131295","journal-title":"J Clin Oncol"},{"key":"5788_CR39","unstructured":"ClinicalTrials.gov (2021) A safety run-in and phase II Study evaluating the efficacy, safety, and impact on the tumor microenvironment of the combination of tocilizumab, atezolizumab, and fractionated stereotactic radiotherapy in recurrent glioblastoma, N.R.G. oncology, editor"},{"issue":"1","key":"5788_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","volume":"6","author":"B Borgelt","year":"1980","unstructured":"Borgelt B et al (1980) The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6(1):1\u20139","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1 Suppl","key":"5788_CR41","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.ijrobp.2007.07.2387","volume":"71","author":"TJ FitzGerald","year":"2008","unstructured":"FitzGerald TJ et al (2008) Processes for quality improvements in radiation oncology clinical trials. Int J Radiat Oncol Biol Phys 71(1 Suppl):S76\u2013S79","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5788_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","volume":"129","author":"L Rogers","year":"2018","unstructured":"Rogers L et al (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129(1):35\u201347","journal-title":"J Neurosurg"},{"issue":"4","key":"5788_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S0360-3016(96)00619-0","volume":"37","author":"L Gaspar","year":"1997","unstructured":"Gaspar L et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745\u2013751","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9422","key":"5788_CR44","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","volume":"363","author":"DW Andrews","year":"2004","unstructured":"Andrews DW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665\u20131672","journal-title":"Lancet"},{"issue":"4","key":"5788_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jamaoncol.2015.1145","volume":"1","author":"H Aoyama","year":"2015","unstructured":"Aoyama H et al (2015) Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99\u2009\u2013\u20091 Randomized Clinical Trial. JAMA Oncol 1(4):457\u2013464","journal-title":"JAMA Oncol"},{"issue":"5","key":"5788_CR46","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ijrobp.2017.07.045","volume":"99","author":"TM Churilla","year":"2017","unstructured":"Churilla TM et al (2017) Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. Int J Radiat Oncol Biol Phys 99(5):1173\u20131178","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5788_CR47","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","volume":"15","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387\u2013395","journal-title":"Lancet Oncol"},{"issue":"13","key":"5788_CR48","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/jama.2026.0076","volume":"335","author":"AA Aizer","year":"2026","unstructured":"Aizer AA et al (2026) Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation: A Randomized Clinical Trial. JAMA 335(13):1127\u20131136","journal-title":"JAMA"},{"key":"5788_CR49","volume-title":"A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases","author":"ClinicalTrials.gov","year":"2018","unstructured":"ClinicalTrials.gov (2018) A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases. O. Alliance for Clinical Trials in and N.R.G. Oncology, Editors"},{"key":"5788_CR50","volume-title":"Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer","author":"ClinicalTrials.gov","year":"2021","unstructured":"ClinicalTrials.gov (2021) Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases From Small Cell Lung Cancer. I. National Cancer, Editor"},{"key":"5788_CR51","unstructured":"ClinicalTrials.gov (2024) Phase III trial of single fraction Stereotactic Radiosurgery (SRS) versus Fractionated SRS (FSRS) for intact brain metastases"},{"issue":"2","key":"5788_CR52","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/j.ijrobp.2011.06.271","volume":"81","author":"S Ryu","year":"2011","unstructured":"Ryu S et al (2011) RTOG 0631 Phase II\/III Study of Image-Guided Stereotactic Radiosurgery for Localized (1\u20133) Spine Metastases: Phase II Results. Int J Radiat Oncol Biol Phys 81(2):S131\u2013s132","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"5788_CR53","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1093\/neuonc\/not114","volume":"15","author":"PD Brown","year":"2013","unstructured":"Brown PD et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 15(10):1429\u20131437","journal-title":"Neuro Oncol"},{"issue":"10","key":"5788_CR54","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD et al (2020) Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 38(10):1019\u20131029","journal-title":"J Clin Oncol"},{"key":"5788_CR55","doi-asserted-by":"publisher","first-page":"111000","DOI":"10.1016\/j.radonc.2025.111000","volume":"209","author":"N Gleim","year":"2025","unstructured":"Gleim N et al (2025) Neuroprotection in radiotherapy of brain metastases - a European pattern-of-care analysis by the ESTRO CNS Focus group. Radiother Oncol 209:111000","journal-title":"Radiother Oncol"},{"issue":"34","key":"5788_CR56","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1200\/JCO.2014.57.2909","volume":"32","author":"V Gondi","year":"2014","unstructured":"Gondi V et al (2014) Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol 32(34):3810\u20133816","journal-title":"J Clin Oncol"},{"issue":"4","key":"5788_CR57","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.adro.2022.100949","volume":"7","author":"V Jairam","year":"2022","unstructured":"Jairam V et al (2022) Practice Patterns Related to Mitigation of Neurocognitive Decline in Patients Receiving Whole Brain Radiation Therapy. Adv Radiat Oncol 7(4):100949","journal-title":"Adv Radiat Oncol"},{"key":"5788_CR58","volume-title":"Randomized Phase II\/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer, I. National Cancer and G","author":"ClinicalTrials.gov","year":"2015","unstructured":"ClinicalTrials.gov (2015) Randomized Phase II\/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer, I. National Cancer and G. Radiation Therapy Oncology, Editors"},{"issue":"6","key":"5788_CR59","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/WCO.0b013e3283322a92","volume":"22","author":"MC Chamberlain","year":"2009","unstructured":"Chamberlain MC (2009) Leptomeningeal metastasis. Curr Opin Neurol 22(6):665\u2013674","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"5788_CR60","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1001\/jamaoncol.2025.3007","volume":"11","author":"JT Yang","year":"2025","unstructured":"Yang JT et al (2025) Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial. JAMA Oncol 11(11):1293\u20131301","journal-title":"JAMA Oncol"},{"issue":"4","key":"5788_CR61","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","volume":"10","author":"LM DeAngelis","year":"1992","unstructured":"DeAngelis LM et al (1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10(4):635\u2013643","journal-title":"J Clin Oncol"},{"issue":"30","key":"5788_CR62","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD et al (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25(30):4730\u20134735","journal-title":"J Clin Oncol"},{"issue":"31","key":"5788_CR63","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG et al (2013) Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 31(31):3971\u20133979","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05788-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:03:23Z","timestamp":1791403403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["5788"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05788-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"3 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and informed consent were not required because this study is a white paper of previously published literature and did not involve individual patient-level data.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.P.M.- Consultant\/Honoraria: Mustang BioTech, Novocure, AIQ, BDT, GT Technologies, Chimerix, Telix; Patents: WARF; Proton PRDR; Leadership Roles: NRG Oncology Brain Tumor Committee Chair; NRG Oncology Board Member; NAPT Board Member; PCG Board Member; Mevion Technological Advisory BoardStock\/Ownership:Pyrojas. K.S.- No COI. M.Y.C.P.- Consultant\/Honoraria: NeuroTrials, LLC; Astellas Pharma; Leadership Roles: member of the NCI Head and Neck Steering Committee; member of the NCI Lymphoma Steering Committee; member of the Psychosis Risk Outcomes Compound Assessment Network (ProCAN) Data and Safety Monitoring Board (DSMB). M.A.V. - founder, director and Chief Technology Officer of Cerinfuse, of which I am the majority shareholder.\u202f I am also founder, director, Chief Medical Officer and a shareholder of Reverix Therapeutics, Inc. M.G.- No COI. A.C.- No COI. D.P.C.- has received honoraria for advisory activities from Boston Scientific (2025) and Servier (2023). A.B.L.- Consultant\/Advisor\/Honoraria: Fore, GSK, GCAR, Immunicom, Modifibio, Nerviano Medical Sciences srl, Orbus, Deciphera, Rigel, Sapience, Servier. Stock: Moderna (divested). Travel\/in-kind support: AnHeart\/Nuvation, Fortrea, Gilead, GCAR, Immunicom, Incyte, Modifibio, MI&amp;T srl, Orbus, Sapience, Servier, VBI. Editorial board (uncompensated): Neuro Oncology (current), Journal of Neuro-oncology (former). D.R.R.- has consulted with GammaTile, Tipping Point, Sirtex, Crinetics, Exelixis, Capvision, and SurvivorNet, is an inventor on patents pertaining to brain tumor treatment and risk-stratification and has served as an expert witness. E.P.S. - Has consulted and received institutional research funding from Novocure; has consulted for Telix, received research funding from SHY-Therapeutics, Purdue Pharma, Curtana, Duke Street Bio. M.M.- Deputy Group Chair and member of the Board of Directors of NRG Oncology; President and member of the Board of Directors of the RTOG Foundation; Research funding (last 5 years): Merck, Astra Zeneca, Genentech, Eli Lilly, Amgen, Consultancy and travel funding: Varian, Astra Zeneca, Caris. Q.T.L. - Leadership Roles: NRG Oncology\/RTOGF group chair; Consultant\/Honoraria: Merck, Johnson&amp;Johnson; Research Grant: Merck. W.C.- Data Monitoring Committee Member: Amgen, Bristol Myers Squibb, AstraZeneca; Shareholder and Board Member: Lumonus; Shareholder: SeeTreat, Nanthealth; Limited Partner: Oncology Ventures Fund; Stock Options: Arterra AI. V.G.- Consultant\/Honoraria: Servier, Novocure, AstraZeneca, GammaTile, Accuray, UpToDate; Leadership Roles: NRG Oncology Brain Tumor Committee Chair.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}